{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:27:15Z","timestamp":1794414435422,"version":"4.9.1"},"reference-count":239,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017291","name":"Zhongshan Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017291","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32271332"],"award-info":[{"award-number":["32271332"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404940"],"award-info":[{"award-number":["82404940"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82341097"],"award-info":[{"award-number":["82341097"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Guangdong Provincial Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.pharmthera.2026.109125","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T22:51:44Z","timestamp":1789253504000},"page":"109125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Galectin-3 and its inhibitors: Overview and perspectives"],"prefix":"10.1016","volume":"288","author":[{"given":"Shuanglin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2026.109125_bb0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4137\/CMO.S29462","article-title":"Galectin-3 as a potential target to prevent cancer metastasis","volume":"9","author":"Ahmed","year":"2015","journal-title":"Clinical Medicine Insights-Oncology"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109125_bb0010","doi-asserted-by":"crossref","first-page":"8116","DOI":"10.3390\/ijms24098116","article-title":"Development of galectin-3 targeting drugs for therapeutic applications in various diseases","volume":"24","author":"Ahmed","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109125_bb0015","first-page":"5272","article-title":"Galectin-3: A novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family","volume":"57","author":"Akahani","year":"1997","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb0020","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ekir.2018.09.013","article-title":"Soluble ST2 and galectin-3 and progression of CKD","volume":"4","author":"Alam","year":"2019","journal-title":"Kidney International Reports"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109125_bb0025","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.3390\/biomedicines9091208","article-title":"Computational study of potential Galectin-3 inhibitors in the treatment of COVID-19","volume":"9","author":"Aminpour","year":"2021","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109125_bb0030","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.1021\/acsomega.9b03461","article-title":"Construction of a stapled \u03b1-Helix peptide library displayed on phage for the screening of Galectin-3-binding peptide ligands","volume":"5","author":"Anananuchatkul","year":"2020","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb0035","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s12967-018-1675-4","article-title":"Galectin-3 predicts response and outcomes after cardiac resynchronization therapy","volume":"16","author":"Andre","year":"2018","journal-title":"Journal of Translational Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109125_bb0040","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2015.1026505","article-title":"Galectin-3 as a regulator of the epithelial junction: Implications to wound repair and cancer","volume":"3","author":"Arg\u00fceso","year":"2015","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0045","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3389\/fnins.2018.00430","article-title":"Investigation of Gal-3 expression pattern in serum and cerebrospinal fluid of patients suffering from neurodegenerative disorders","volume":"12","author":"Ashraf","year":"2018","journal-title":"Frontiers in Neuroscience"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109125_bb0050","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00280-023-04513-y","article-title":"Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: A single- and multiple-dose first-in-human study in healthy participants","volume":"91","author":"Aslanis","year":"2023","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109125_bb0055","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.jacc.2019.02.046","article-title":"Galectin-3 levels and outcomes after myocardial infarction: A population-based study","volume":"73","author":"Asleh","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109125_bb0060","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bbrc.2017.05.150","article-title":"Biophysical and structural characterization of mono\/di-arylated lactosamine derivatives interaction with human galectin-3","volume":"489","author":"Atmanene","year":"2017","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"Pt 8","key":"10.1016\/j.pharmthera.2026.109125_bb0065","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1242\/jcs.108.8.2791","article-title":"Galectin-3 expression and effects on cyst enlargement and tubulogenesis in kidney epithelial MDCK cells cultured in three-dimensional matrices in vitro","volume":"108","author":"Bao","year":"1995","journal-title":"Journal of Cell Science"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109125_bb0070","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0092-8674(94)90498-7","article-title":"Galectins: A family of animal \u03b2-galactoside-binding lectins","volume":"76","author":"Barondes","year":"1994","journal-title":"Cell"},{"issue":"33","key":"10.1016\/j.pharmthera.2026.109125_bb0075","doi-asserted-by":"crossref","first-page":"20807","DOI":"10.1016\/S0021-9258(17)31891-4","article-title":"Galectins. Structure and function of a large family of animal lectins","volume":"269","author":"Barondes","year":"1994","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0080","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3389\/fchem.2020.00593","article-title":"Targeting galectins with Glycomimetics","volume":"8","author":"Bertuzzi","year":"2020","journal-title":"Frontiers in Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb0085","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/glycob\/cwj035","article-title":"Exploring the role of galectin 3 in kidney function: A genetic approach","volume":"16","author":"Bichara","year":"2006","journal-title":"Glycobiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109125_bb0090","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11060-012-1005-2","article-title":"Galectin-3 in preneoplastic lesions of glioma","volume":"111","author":"Binh","year":"2013","journal-title":"Journal of Neuro-Oncology"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109125_bb0095","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.3390\/cancers13194819","article-title":"Increased circulating levels of galectin proteins in patients with breast, colon, and lung cancer","volume":"13","author":"Blair","year":"2021","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109125_bb0100","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1071\/CH14362","article-title":"Inhibitors of galectins and implications for structure-based design of galectin-specific therapeutics","volume":"67","author":"Blanchard","year":"2014","journal-title":"Australian Journal of Chemistry"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109125_bb0105","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1517\/13543776.2014.947961","article-title":"Galectin-3 inhibitors: A patent review (2008-present)","volume":"24","author":"Blanchard","year":"2014","journal-title":"Expert Opinion on Therapeutic Patents"},{"issue":"49","key":"10.1016\/j.pharmthera.2026.109125_bb0110","doi-asserted-by":"crossref","first-page":"17033","DOI":"10.1073\/pnas.0407902101","article-title":"Printed covalent glycan array for ligand profiling of diverse glycan binding proteins","volume":"101","author":"Blixt","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"25","key":"10.1016\/j.pharmthera.2026.109125_bb0115","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1038\/onc.2013.272","article-title":"Inflammatory chemokines and metastasis\u2014Tracing the accessory","volume":"33","author":"Borsig","year":"2013","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109125_bb0120","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ceb.2011.05.001","article-title":"Glycosylation, galectins and cellular signaling","volume":"23","author":"Boscher","year":"2011","journal-title":"Current Opinion in Cell Biology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109125_bb0125","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00401-019-02013-z","article-title":"Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer's disease","volume":"138","author":"Boza-Serrano","year":"2019","journal-title":"Acta Neuropathologica"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109125_bb0130","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1021\/acs.jmedchem.9b01692","article-title":"In vivo Veritas: (18)F-radiolabeled Glycomimetics allow insights into the pharmacological fate of Galectin-3 inhibitors","volume":"63","author":"Bratteby","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0135","series-title":"Novel Hybrid Galactoside Inhibitor of Galectins. US2022289783 (Vol. WO 2016\/113335 A1)","author":"Brimert","year":"2016"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109125_bb0140","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.1021\/acs.jmedchem.1c01296","article-title":"Novel selective Galectin-3 antagonists are cytotoxic to acute lymphoblastic leukemia","volume":"65","author":"Bum-Erdene","year":"2022","journal-title":"Journal of Medicinal Chemistry"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109125_bb0145","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/cbic.201300245","article-title":"Investigation into the feasibility of thioditaloside as a novel scaffold for galectin-3-specific inhibitors","volume":"14","author":"Bum-Erdene","year":"2013","journal-title":"Chembiochem"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109125_bb0150","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.1021\/jo500883v","article-title":"Design and synthesis of hydrolytically stable multivalent ligands bearing thiodigalactoside analogues for peanut lectin and human galectin-3 binding","volume":"79","author":"Cagnoni","year":"2014","journal-title":"Journal of Organic Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2023.121668","article-title":"Functional structural domain synthesis of anti-pancreatic carcinoma pectin-like polysaccharide RN1","volume":"327","author":"Cai","year":"2024","journal-title":"Carbohydrate Polymers"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb0160","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jchf.2014.08.002","article-title":"The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries","volume":"3","author":"Calvier","year":"2015","journal-title":"JACC-Heart Failure"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109125_bb0165","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s10719-016-9721-z","article-title":"Synthetic glycoconjugates inhibitors of tumor-related galectin-3: An update","volume":"33","author":"Campo","year":"2016","journal-title":"Glycoconjugate Journal"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109125_bb0170","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1016\/j.apsb.2022.05.020","article-title":"Carbohydrate-based drugs launched during 2000\u22122021","volume":"12","author":"Cao","year":"2022","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109125_bb0175","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3390\/ijms20071607","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy: The galectin-3 signature in NSCLCs","volume":"20","author":"Capalbo","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109125_bb0180","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/glycob\/cwm026","article-title":"Affinity of galectin-8 and its carbohydrate recognition domains for ligands in solution and at the cell surface","volume":"17","author":"Carlsson","year":"2007","journal-title":"Glycobiology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109125_bb0185","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.tibs.2016.11.003","article-title":"Translating the \u2018sugar code\u2019 into immune and vascular signaling programs","volume":"42","author":"Cerliani","year":"2017","journal-title":"Trends in Biochemical Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109125_bb0190","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/ijms19020392","article-title":"Dissecting the structure\u2013activity relationship of galectin\u2013ligand interactions","volume":"19","author":"Chan","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109125_bb0195","doi-asserted-by":"crossref","first-page":"8350","DOI":"10.1158\/0008-5472.CAN-05-0163","article-title":"A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells","volume":"65","author":"Chauhan","year":"2005","journal-title":"Cancer Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109125_bb0200","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3390\/ijms17040565","article-title":"The role of galectin-3 in the kidneys","volume":"17","author":"Chen","year":"2016","journal-title":"International Journal of Molecular Sciences"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109125_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201517","article-title":"Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure","volume":"13","author":"Clementy","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109125_bb0210","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1747-0285.2011.01283.x","article-title":"Taloside inhibitors of galectin-1 and galectin-3","volume":"79","author":"Collins","year":"2012","journal-title":"Chemical Biology & Drug Design"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109125_bb0215","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1074\/jbc.M117.783431","article-title":"Galectin-3 interacts with the cell-surface glycoprotein CD146 (MCAM, MUC18) and induces secretion of metastasis-promoting cytokines from vascular endothelial cells","volume":"292","author":"Colomb","year":"2017","journal-title":"Journal of Biological Chemistry"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109125_bb0220","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nrcardio.2010.51","article-title":"Early detection of myocardial dysfunction and heart failure","volume":"7","author":"de Couto","year":"2010","journal-title":"Nature Reviews Cardiology"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0225","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.12659\/MSM.908840","article-title":"Differential and predictive value of galectin-3 and soluble suppression of tumorigenicity-2 (sST2) in heart failure with preserved ejection fraction","volume":"24","author":"Cui","year":"2018","journal-title":"Medical Science Monitor"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109125_bb0230","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1039\/b502354h","article-title":"Synthesis of a phenyl thio-\u03b2-D-galactopyranoside library from 1,5-difluoro-2,4-dinitrobenzene: Discovery of efficient and selective monosaccharide inhibitors of galectin-7","volume":"3","author":"Cumpstey","year":"2005","journal-title":"Organic & Biomolecular Chemistry"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109125_bb0235","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1002\/chem.200701932","article-title":"Double affinity amplification of galectin\u2013ligand interactions through arginine\u2013arene interactions: Synthetic, thermodynamic, and computational studies with aromatic diamido thiodigalactosides","volume":"14","author":"Cumpstey","year":"2008","journal-title":"Chemistry--A European Journal"},{"issue":"32","key":"10.1016\/j.pharmthera.2026.109125_bb0240","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1002\/anie.200500627","article-title":"C2-symmetrical thiodigalactoside bis-benzamido derivatives as high-affinity inhibitors of galectin-3: Efficient lectin inhibition through double arginine-arene interactions","volume":"44","author":"Cumpstey","year":"2005","journal-title":"Angewandte Chemie International Edition in English"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109125_bb0245","article-title":"Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor","volume":"9","author":"Curti","year":"2021","journal-title":"Journal of Immunotherapy"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109125_bb0250","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1073\/pnas.92.4.1213","article-title":"Identification of galectin-3 as a factor in pre-mRNA splicing","volume":"92","author":"Dagher","year":"1995","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109125_bb0255","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1039\/C9MD00183B","article-title":"Aminopyrimidine-galactose hybrids are highly selective galectin-3 inhibitors","volume":"10","author":"Dahlqvist","year":"2019","journal-title":"Medchemcomm"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109125_bb0260","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.apsb.2021.01.018","article-title":"AncPhore: A versatile tool for anchor pharmacophore steered drug discovery with applications in discovery of new inhibitors targeting metallo-\u03b2-lactamases and indoleamine\/tryptophan 2,3-dioxygenases","volume":"11","author":"Dai","year":"2021","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109125_bb0265","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/cbic.201600285","article-title":"Galectin-3-binding Glycomimetics that strongly reduce bleomycin-induced lung fibrosis and modulate intracellular glycan recognition","volume":"17","author":"Delaine","year":"2016","journal-title":"Chembiochem"},{"issue":"24","key":"10.1016\/j.pharmthera.2026.109125_bb0270","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1021\/jm801077j","article-title":"Galectin-inhibitory thiodigalactoside ester derivatives have antimigratory effects in cultured lung and prostate cancer cells","volume":"51","author":"Delaine","year":"2008","journal-title":"Journal of Medicinal Chemistry"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109125_bb0275","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1158\/1078-0432.CCR-13-2459","article-title":"A short treatment with galactomannan GM-CT-01 corrects the functions of freshly isolated human tumor\u2013infiltrating lymphocytes","volume":"20","author":"Demotte","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109125_bb0280","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.autrev.2008.11.009","article-title":"The immunological potential of galectin-1 and -3","volume":"8","author":"Dhirapong","year":"2009","journal-title":"Autoimmunity Reviews"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109125_bb0285","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.3390\/ijms23052581","article-title":"Design, synthesis, and anticancer activity of a selenium-containing galectin-3 and galectin-9N inhibitor","volume":"23","author":"Di Gaetano","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"41","key":"10.1016\/j.pharmthera.2026.109125_bb0290","doi-asserted-by":"crossref","first-page":"14577","DOI":"10.1021\/ja105852y","article-title":"Protein flexibility and conformational entropy in ligand design targeting the carbohydrate recognition domain of galectin-3","volume":"132","author":"Diehl","year":"2010","journal-title":"Journal of the American Chemical Society"},{"issue":"16","key":"10.1016\/j.pharmthera.2026.109125_bb0295","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1158\/0008-5472.CAN-15-0834","article-title":"Galectin-binding O-glycosylations as regulators of malignancy","volume":"75","author":"Dimitroff","year":"2015","journal-title":"Cancer Research"},{"issue":"24","key":"10.1016\/j.pharmthera.2026.109125_bb0300","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1002\/cbic.201700544","article-title":"Development of a sensitive microarray platform for the ranking of galectin inhibitors: Identification of a selective Galectin-3 inhibitor","volume":"18","author":"Dion","year":"2017","journal-title":"Chembiochem"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb0305","doi-asserted-by":"crossref","first-page":"125","DOI":"10.21873\/anticanres.11297","article-title":"Galectin-3 is implicated in tumor progression and resistance to anti-androgen drug through regulation of androgen receptor signaling in prostate Cancer","volume":"37","author":"Dondoo","year":"2017","journal-title":"Anticancer Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109125_bb0310","first-page":"599","article-title":"Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (review)","volume":"41","author":"Dong","year":"2018","journal-title":"International Journal of Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0315","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cca.2018.08.042","article-title":"Exploring collagen remodeling and regulation as prognosis biomarkers in stable heart failure","volume":"490","author":"Dupuy","year":"2019","journal-title":"Clinica Chimica Acta"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109125_bb0320","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1007\/s00018-007-7044-8","article-title":"Galectins: Matricellular glycan-binding proteins linking cell adhesion, migration, and survival","volume":"64","author":"Elola","year":"2007","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108028","article-title":"Galectin-3 level in idiopathic pulmonary fibrosis patients and its relationship with response to antifibrotic treatment","volume":"240","author":"Emre","year":"2025","journal-title":"Respiratory Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109125_bb0330","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/s41401-018-0004-z","article-title":"Modified citrus pectin inhibited bladder tumor growth through downregulation of galectin-3","volume":"39","author":"Fang","year":"2018","journal-title":"Acta Pharmacologica Sinica"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109125_bb0335","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1434467","article-title":"The role of galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment","volume":"7","author":"Farhad","year":"2018","journal-title":"OncoImmunology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109125_bb0340","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/glycob\/cwi026","article-title":"Galectin-3 and soluble fibrinogen act in concert to modulate neutrophil activation and survival: Involvement of alternative MAPK pathways","volume":"15","author":"Fern\u00e1ndez","year":"2005","journal-title":"Glycobiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb0345","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nm1332","article-title":"IL-13 signaling through the IL-13\u03b12 receptor is involved in induction of TGF-\u03b21 production and fibrosis","volume":"12","author":"Fichtner-Feigl","year":"2005","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0350","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fonc.2014.00138","article-title":"Extracellular galectin-3 in tumor progression and metastasis","volume":"4","author":"Fortuna-Costa","year":"2014","journal-title":"Frontiers in Oncology"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109125_bb0355","first-page":"8302","article-title":"CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis","volume":"63","author":"Fukumori","year":"2003","journal-title":"Cancer Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109125_bb0360","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/glycob\/cwu086","article-title":"Galectin-3 in angiogenesis and metastasis","volume":"24","author":"Funasaka","year":"2014","journal-title":"Glycobiology"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109125_bb0365","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1021\/acsmedchemlett.0c00330","article-title":"Quinoline-Pyrazole scaffold as a novel ligand of Galectin-3 and suppressor of TREM2 signaling","volume":"11","author":"Gabr","year":"2020","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109125_bb0370","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10719-012-9382-5","article-title":"Analysis of the neutral polysaccharide fraction of MCP and its inhibitory activity on galectin-3","volume":"29","author":"Gao","year":"2012","journal-title":"Glycoconjugate Journal"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0375","doi-asserted-by":"crossref","first-page":"5284728","DOI":"10.1155\/2020\/5284728","article-title":"Galectin-3 is a potential mediator for atherosclerosis","volume":"2020","author":"Gao","year":"2020","journal-title":"Journal of Immunology Research"},{"issue":"25","key":"10.1016\/j.pharmthera.2026.109125_bb0380","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1016\/j.jacc.2018.09.076","article-title":"Longitudinal change in galectin-3 and incident cardiovascular outcomes","volume":"72","author":"Ghorbani","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"issue":"172","key":"10.1016\/j.pharmthera.2026.109125_bb0385","doi-asserted-by":"crossref","first-page":"SE211","DOI":"10.4052\/tigg.1744.1SE","article-title":"Clinical trials and applications of galectin antagonists","volume":"30","author":"Girard","year":"2018","journal-title":"Trends in Glycoscience and Glycotechnology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109125_bb0390","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20182041","article-title":"Sweetening the hallmarks of cancer: Galectins as multifunctional mediators of tumor progression","volume":"217","author":"Girotti","year":"2020","journal-title":"Journal of Experimental Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109125_bb0395","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011100","article-title":"Galectin-3 is associated with stage B metabolic heart disease and pulmonary hypertension in young obese patients","volume":"8","author":"Gopal","year":"2019","journal-title":"Journal of the American Heart Association"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb0400","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and Cancer: Triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109125_bb0405","doi-asserted-by":"crossref","first-page":"18183","DOI":"10.18632\/oncotarget.7784","article-title":"Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets","volume":"7","author":"Grosset","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb0410","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1038\/s41467-021-23494-1","article-title":"SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care","volume":"12","author":"Gutmann","year":"2021","journal-title":"Nature Communications"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109125_bb0415","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3390\/biom10030389","article-title":"Galectin-3 as a next-generation biomarker for detecting early stage of various diseases","volume":"10","author":"Hara","year":"2020","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109125_bb0420","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.carpath.2014.12.001","article-title":"Galectin-3 is expressed in the myocardium very early post-myocardial infarction","volume":"24","author":"Hashmi","year":"2015","journal-title":"Cardiovascular Pathology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109125_bb0425","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1021\/jm301677r","article-title":"Tuning the preference of thiodigalactoside- and lactosamine-based ligands to galectin-3 over galectin-1","volume":"56","author":"van Hattum","year":"2013","journal-title":"Journal of Medicinal Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109125_bb0430","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/07328303.2019.1609022","article-title":"Design, synthesis and evaluation of lactoside-derived galectin-3 inhibitors","volume":"38","author":"He","year":"2019","journal-title":"Journal of Carbohydrate Chemistry"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109125_bb0435","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2353\/ajpath.2008.070726","article-title":"Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis","volume":"172","author":"Henderson","year":"2008","journal-title":"American Journal of Pathology"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109125_bb0440","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1073\/pnas.0511167103","article-title":"Galectin-3 regulates myofibroblast activation and hepatic fibrosis","volume":"103","author":"Henderson","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb0445","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1600-065X.2009.00794.x","article-title":"The regulation of inflammation by galectin-3","volume":"230","author":"Henderson","year":"2009","journal-title":"Immunological Reviews"},{"issue":"2\u20133","key":"10.1016\/j.pharmthera.2026.109125_bb0450","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0304-4165(02)00311-2","article-title":"Oligosaccharide specificity of galectins: A search by frontal affinity chromatography","volume":"1572","author":"Hirabayashi","year":"2002","journal-title":"Biochimica et Biophysica Acta-General Subjects"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109125_bb0455","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02559-2020","article-title":"Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis","volume":"57","author":"Hirani","year":"2021","journal-title":"European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0460","doi-asserted-by":"crossref","first-page":"897","DOI":"10.5114\/aoms.2016.58664","article-title":"Potential novel biomarkers of cardiovascular dysfunction and disease: Cardiotrophin-1, adipokines and galectin-3","volume":"4","author":"Hogas","year":"2017","journal-title":"Archives of Medical Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb0465","doi-asserted-by":"crossref","first-page":"29457","DOI":"10.1038\/srep29457","article-title":"Dual thio-digalactoside-binding modes of human galectins as the structural basis for the design of potent and selective inhibitors","volume":"6","author":"Hsieh","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0470","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/978-1-4939-1396-1_29","article-title":"Analysis of the intracellular role of galectins in cell growth and apoptosis","volume":"1207","author":"Hsu","year":"2015","journal-title":"Methods in Molecular Biology"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109125_bb0475","article-title":"Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial","volume":"13","author":"Huang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0480","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.949264","article-title":"Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation","volume":"13","author":"Humphries","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109125_bb0485","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jhep.2010.09.020","article-title":"Galectin-3 ablation protects mice from diet-induced NASH: A major scavenging role for galectin-3 in liver","volume":"54","author":"Iacobini","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"15","key":"10.1016\/j.pharmthera.2026.109125_bb0490","first-page":"3267","article-title":"Functional evidence that cell surface galectin-3 mediates homotypic cell adhesion","volume":"55","author":"Inohara","year":"1995","journal-title":"Cancer Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109125_bb0495","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1476-5381.2012.01847.x","article-title":"cAMP and Epac in the regulation of tissue fibrosis","volume":"166","author":"Insel","year":"2012","journal-title":"British Journal of Pharmacology"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109125_bb0500","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s00894-018-3831-4","article-title":"Bergenin: A computationally proven promising scaffold for novel galectin-3 inhibitors","volume":"24","author":"Jayakody","year":"2018","journal-title":"Journal of Molecular Modeling"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109125_bb0505","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.molmed.2024.11.006","article-title":"Galectin-3 in metabolic disorders: Mechanisms and therapeutic potential","volume":"31","author":"Jiang","year":"2025","journal-title":"Trends in Molecular Medicine"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109125_bb0510","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.208884","article-title":"Galectins at a glance","volume":"131","author":"Johannes","year":"2018","journal-title":"Journal of Cell Science"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109125_bb0515","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/(SICI)1096-9896(199607)179:3<309::AID-PATH572>3.0.CO;2-D","article-title":"Immunocytochemical evidence for a modulation of galectin 3 (Mac-2), a carbohydrate binding protein, in pulmonary fibrosis","volume":"179","author":"Kasper","year":"1996","journal-title":"Journal of Pathology"},{"issue":"16","key":"10.1016\/j.pharmthera.2026.109125_bb0520","first-page":"4148","article-title":"Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells","volume":"59","author":"Kim","year":"1999","journal-title":"Cancer Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109125_bb0525","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1007\/s10120-021-01186-5","article-title":"Crosstalk between WNT and STAT3 is mediated by galectin-3 in tumor progression","volume":"24","author":"Kim","year":"2021","journal-title":"Gastric Cancer"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109125_bb0530","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/cbdd.13348","article-title":"Lactulose as a novel template for anticancer drug development targeting galectins","volume":"92","author":"Kishor","year":"2018","journal-title":"Chemical Biology & Drug Design"},{"issue":"29","key":"10.1016\/j.pharmthera.2026.109125_bb0535","doi-asserted-by":"crossref","first-page":"18973","DOI":"10.1039\/D2RA03163A","article-title":"Design and synthesis of novel 3-triazolyl-1-thiogalactosides as galectin-1, \u22123 and \u22128 inhibitors","volume":"12","author":"van Klaveren","year":"2022","journal-title":"RSC Advances"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0540","first-page":"3","article-title":"Galectins in disease and potential therapeutic approaches. In galectins and disease implications for targeted therapeutics","volume":"January 1","author":"Klyosov","year":"2012","journal-title":"American Chemical Society"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109125_bb0545","doi-asserted-by":"crossref","first-page":"14940","DOI":"10.1016\/S0021-9258(18)82423-1","article-title":"Carbohydrate-binding protein 35. II. Analysis of the interaction of the recombinant polypeptide with saccharides","volume":"268","author":"Knibbs","year":"1993","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0550","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.neulet.2015.02.061","article-title":"Early microlesion of viral encephalitis confirmed by galectin-3 expression after a virus inoculation","volume":"592","author":"Kobayashi","year":"2015","journal-title":"Neuroscience Letters"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109125_bb0555","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1158\/2326-6066.CIR-14-0150","article-title":"Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells","volume":"3","author":"Kouo","year":"2015","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0560","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1052959","article-title":"Galectin functions in cancer-associated inflammation and thrombosis","volume":"10","author":"Kruk","year":"2023","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109125_bb0565","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4103\/ijem.ijem_270_22","article-title":"Galectin-3 as a potential biomarker of microvascular complications in patients with type 2 diabetes","volume":"26","author":"Kumar","year":"2022","journal-title":"Indian Journal of Endocrinology and Metabolism"},{"issue":"7\u20139","key":"10.1016\/j.pharmthera.2026.109125_bb0570","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1023\/B:GLYC.0000014072.34840.04","article-title":"Introduction to galectins","volume":"19","author":"Leffler","year":"2002","journal-title":"Glycoconjugate Journal"},{"issue":"26","key":"10.1016\/j.pharmthera.2026.109125_bb0575","doi-asserted-by":"crossref","first-page":"21751","DOI":"10.1074\/jbc.C112.358002","article-title":"Ligand induced galectin-3 protein self-association","volume":"287","author":"Lepur","year":"2012","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb0580","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","article-title":"Structure, function, and evolution of coronavirus spike proteins","volume":"3","author":"Li","year":"2016","journal-title":"Annual Review of Virology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109125_bb0585","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.114.218370","article-title":"Functions of galectin-3 and its role in fibrotic diseases","volume":"351","author":"Li","year":"2014","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109125_bb0590","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cell.2016.10.025","article-title":"Hematopoietic-derived galectin-3 causes cellular and systemic insulin resistance","volume":"167","author":"Li","year":"2016","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109125_bb0595","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1158\/1541-7786.MCR-09-0274","article-title":"Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer","volume":"7","author":"Lin","year":"2009","journal-title":"Molecular Cancer Research"},{"issue":"16","key":"10.1016\/j.pharmthera.2026.109125_bb0600","doi-asserted-by":"crossref","first-page":"11084","DOI":"10.1021\/acs.jmedchem.2c00517","article-title":"Identification of monosaccharide derivatives as potent, selective, and orally bioavailable inhibitors of human and mouse Galectin-3","volume":"65","author":"Liu","year":"2022","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0605","series-title":"Small Molecule Inhibitors of Galectin-3","author":"Liu","year":"2020"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb0610","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrc1527","article-title":"Galectins as modulators of tumour progression","volume":"5","author":"Liu","year":"2005","journal-title":"Nature Reviews Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109125_bb0615","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1021\/bm034340z","article-title":"Comparative cell response to artificial extracellular matrix proteins containing the RGD and CS5 cell-binding domains","volume":"5","author":"Liu","year":"2004","journal-title":"Biomacromolecules"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109125_bb0620","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109125_bb0625","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1073\/pnas.1813515116","article-title":"Design\u2013functionality relationships for adhesion\/growth-regulatory galectins","volume":"116","author":"Ludwig","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JIR.S572637","article-title":"The role of Galectin-3 in liver inflammation and fibrosis","volume":"19","author":"Lurje","year":"2026","journal-title":"Journal of Inflammation Research"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0635","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1250559","article-title":"Resistance to anti-PD-1\/anti-PD-L1: Galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1\/PD-L1","volume":"14","author":"Mabbitt","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109125_bb0640","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.4049\/jimmunol.180.4.2650","article-title":"Regulation of alternative macrophage activation by galectin-3","volume":"180","author":"MacKinnon","year":"2008","journal-title":"Journal of Immunology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109125_bb0645","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1164\/rccm.201106-0965OC","article-title":"Regulation of transforming growth factor-\u03b21\u2013driven lung fibrosis by galectin-3","volume":"185","author":"MacKinnon","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109125_bb0650","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/glycob\/cwt006","article-title":"Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice","volume":"23","author":"MacKinnon","year":"2013","journal-title":"Glycobiology"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109125_bb0655","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/14728222.2023.2258280","article-title":"Galectin-3: Therapeutic targeting in liver disease","volume":"27","author":"Mackinnon","year":"2023","journal-title":"Expert Opinion on Therapeutic Targets"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109125_bb0660","doi-asserted-by":"crossref","first-page":"14716","DOI":"10.1021\/acs.jmedchem.3c01223","article-title":"Ligand sulfur oxidation state progressively alters galectin-3-ligand complex conformations to induce affinity-influencing hydrogen bonds","volume":"66","author":"Mahanti","year":"2023","journal-title":"Journal of Medicinal Chemistry"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109125_bb0665","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1016\/j.bmc.2015.04.044","article-title":"Synthetic 1,2,3-triazole-linked glycoconjugates bind with high affinity to human galectin-3","volume":"23","author":"Marchiori","year":"2015","journal-title":"Bioorganic & Medicinal Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109125_bb0670","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41573-023-00636-2","article-title":"Targeting galectin-driven regulatory circuits in cancer and fibrosis","volume":"22","author":"Mari\u00f1o","year":"2023","journal-title":"Nature Reviews Drug Discovery"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109125_bb0675","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/ijo.2016.19","article-title":"Galectin-3 inhibition prevents adipose tissue remodelling in obesity","volume":"40","author":"Mart\u00ednez-Mart\u00ednez","year":"2016","journal-title":"International Journal of Obesity"},{"issue":"33","key":"10.1016\/j.pharmthera.2026.109125_bb0680","first-page":"1","article-title":"Role of galectin-3 in obesity and impaired glucose homeostasis","volume":"2016","author":"Menini","year":"2016","journal-title":"Oxidative Medicine and Cellular Longevity"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb0685","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.clim.2008.08.024","article-title":"Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice","volume":"130","author":"Mensah-Brown","year":"2009","journal-title":"Clinical Immunology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109125_bb0690","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2022.12682","article-title":"The role of galectins-1, 3, 7, 8 and 9 as potential diagnostic and therapeutic markers in ovarian cancer (review)","volume":"25","author":"Mielczarek-palacz","year":"2022","journal-title":"Molecular Medicine Reports"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109125_bb0695","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/glycob\/cwp084","article-title":"The \u03b1-galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain","volume":"19","author":"Miller","year":"2009","journal-title":"Glycobiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109125_bb0700","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3390\/ijms26020790","article-title":"Galectins and liver diseases","volume":"26","author":"Mimura","year":"2025","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109125_bb0705","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3343\/alm.2018.38.4.331","article-title":"Usefulness of enhanced liver fibrosis, glycosylation isomer of mac-2 binding protein, galectin-3, and soluble suppression of tumorigenicity 2 for assessing liver fibrosis in chronic liver diseases","volume":"38","author":"Moon","year":"2018","journal-title":"Annals of Laboratory Medicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109125_bb0710","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrd.2017.170","article-title":"Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease","volume":"16","author":"Mora","year":"2017","journal-title":"Nature Reviews Drug Discovery"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109125_bb0715","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1242\/jcs.151159","article-title":"The galectin lattice at a glance","volume":"128","author":"Nabi","year":"2015","journal-title":"Journal of Cell Science"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109125_bb0720","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1158\/0008-5472.CAN-15-1793","article-title":"Galectin-3 cleavage alters bone remodeling: Different outcomes in breast and prostate cancer skeletal metastasis","volume":"76","author":"Nakajima","year":"2016","journal-title":"Cancer Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109125_bb0725","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/glycob\/cwy001","article-title":"Galectin-3 and cancer stemness","volume":"28","author":"Nangia-Makker","year":"2018","journal-title":"Glycobiology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109125_bb0730","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/JLB.5MR0822-673R","article-title":"Galectin-3 as a biomarker in breast neoplasms: Mechanisms and applications in patient care","volume":"112","author":"Niang","year":"2022","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0735","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12014-017-9146-0","article-title":"A review of studies of the proteomes of circulating microparticles: Key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosus","volume":"14","author":"Nielsen","year":"2017","journal-title":"Clinical Proteomics"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109125_bb0740","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1074\/jbc.M604506200","article-title":"Visualization of galectin-3 oligomerization on the surface of neutrophils and endothelial cells using fluorescence resonance energy transfer","volume":"282","author":"Nieminen","year":"2007","journal-title":"Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109125_bb0745","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1189\/jlb.1204702","article-title":"Galectin-3 interacts with naive and primed neutrophils, inducing innate immune responses","volume":"78","author":"Nieminen","year":"2005","journal-title":"Journal of Leukocyte Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb0750","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210971","article-title":"Time-course analysis of cardiac and serum galectin-3 in viral myocarditis after an encephalomyocarditis virus inoculation","volume":"14","author":"Noguchi","year":"2019","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109125_bb0755","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1016\/j.bmcl.2008.05.066","article-title":"Protein subtype-targeting through ligand epimerization: Talose-selectivity of galectin-4 and galectin-8","volume":"18","author":"\u00d6berg","year":"2008","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109125_bb0760","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1021\/jm701266y","article-title":"Arginine binding motifs: Design and synthesis of galactose-derived arginine tweezers as galectin-3 inhibitors","volume":"51","author":"\u00d6berg","year":"2008","journal-title":"Journal of Medicinal Chemistry"},{"issue":"29","key":"10.1016\/j.pharmthera.2026.109125_bb0765","doi-asserted-by":"crossref","first-page":"8139","DOI":"10.1002\/chem.201003247","article-title":"Arene\u2013Anion based arginine-Binding motif on a galactose scaffold: structure\u2013activity relationships of interactions with arginine-rich galectins","volume":"17","author":"\u00d6berg","year":"2011","journal-title":"Chemistry--A European Journal"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109125_bb0770","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1006\/bbrc.1998.8708","article-title":"Regulation of cellular adhesion to extracellular matrix proteins by galectin-3","volume":"246","author":"Ochieng","year":"1998","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109125_bb0775","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1189\/jlb.1206747","article-title":"Kinetics of mobilization and differentiation of lymphohematopoietic cells during experimental murine schistosomiasis in galectin-3 \u2212\/\u2212 mice","volume":"82","author":"Oliveira","year":"2007","journal-title":"Journal of Leukocyte Biology"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109125_bb0780","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1177\/1535370215593826","article-title":"Galectin-3 in autoimmunity and autoimmune diseases","volume":"240","author":"de Oliveira","year":"2015","journal-title":"Experimental Biology and Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109125_bb0785","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/14653249.2011.637668","article-title":"Reduction of galectin-3 expression and liver fibrosis after cell therapy in a mouse model of cirrhosis","volume":"14","author":"de Oliveira","year":"2012","journal-title":"Cytotherapy"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116974","article-title":"Synthesis, binding affinity, and inhibitory capacity of cyclodextrin-based multivalent glycan ligands for human galectin-3","volume":"72","author":"Ou","year":"2022","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0795","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.178041","article-title":"Feasibility of galectin-3 as a diagnostic biomarker and therapeutic target for inflammatory bowel disease","volume":"1005","author":"Pan","year":"2025","journal-title":"European Journal of Pharmacology"},{"issue":"5693","key":"10.1016\/j.pharmthera.2026.109125_bb0800","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1126\/science.1102109","article-title":"Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis","volume":"306","author":"Partridge","year":"2004","journal-title":"Science"},{"issue":"26","key":"10.1016\/j.pharmthera.2026.109125_bb0805","doi-asserted-by":"crossref","first-page":"10696","DOI":"10.1073\/pnas.1104306108","article-title":"Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor","volume":"108","author":"Peng","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109125_bb0810","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1042\/BCJ20200167","article-title":"Reprogramming the tumor metastasis cascade by targeting galectin-driven networks","volume":"478","author":"Perrotta","year":"2021","journal-title":"Biochemical Journal"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109125_bb0815","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1021\/acs.jmedchem.7b01626","article-title":"Systematic tuning of Fluoro-galectin-3 interactions provides Thiodigalactoside derivatives with single-digit nM affinity and high selectivity","volume":"61","author":"Peterson","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb0820","doi-asserted-by":"crossref","DOI":"10.1016\/j.retram.2021.103321","article-title":"Pectins from various sources inhibit galectin-3-related cardiac fibrosis","volume":"70","author":"Pozder geb. Gehlken","year":"2022","journal-title":"Current Research in Translational Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109125_bb0825","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/glycob\/cwj056","article-title":"Synthetic lactulose amines: Novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis","volume":"16","author":"Rabinovich","year":"2006","journal-title":"Glycobiology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109125_bb0830","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nri2536","article-title":"Turning \u201csweet\u201d on immunity: Galectin\u2013glycan interactions in immune tolerance and inflammation","volume":"9","author":"Rabinovich","year":"2009","journal-title":"Nature Reviews Immunology"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0835","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.893365","article-title":"N-glycosylation and inflammation; the not-so-sweet relation","volume":"13","author":"Radovani","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"15","key":"10.1016\/j.pharmthera.2026.109125_bb0840","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1016\/j.bmcl.2014.05.063","article-title":"Synthesis and evaluation of iminocoumaryl and coumaryl derivatized glycosides as galectin antagonists","volume":"24","author":"Rajput","year":"2014","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109125_bb0845","doi-asserted-by":"crossref","first-page":"8141","DOI":"10.1021\/acs.jmedchem.6b00957","article-title":"A selective galactose-Coumarin-derived Galectin-3 inhibitor demonstrates involvement of Galectin-3-glycan interactions in a pulmonary fibrosis model","volume":"59","author":"Rajput","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb0850","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/187152008783330833","article-title":"Biological modulation by lectins and their ligands in tumor progression and metastasis","volume":"8","author":"Raz","year":"2008","journal-title":"Anti-Cancer Agents in Medicinal Chemistry"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109125_bb0855","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1158\/2159-8290.CD-13-0760","article-title":"Aberrant glycosylation promotes lung cancer metastasis through adhesion to galectins in the metastatic niche","volume":"5","author":"Reticker-Flynn","year":"2015","journal-title":"Cancer Discovery"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109125_bb0860","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/jcb.10144","article-title":"Interleukin-4 regulates connective tissue growth factor expression in human lung fibroblasts","volume":"85","author":"Rishikof","year":"2002","journal-title":"Journal of Cellular Biochemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb0865","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41420-025-02452-6","article-title":"Galectin-3: A novel biomarker of glycogen storage disease type III","volume":"11","author":"Rossiaud","year":"2025","journal-title":"Cell Death Discovery"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2026.109125_bb0870","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s12031-009-9186-7","article-title":"The role of Galectin-3\/MAC-2 in the activation of the innate-immune function of phagocytosis in microglia in injury and disease","volume":"39","author":"Rotshenker","year":"2009","journal-title":"Journal of Molecular Neuroscience"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109125_bb0875","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.bbamcr.2015.08.008","article-title":"Galectin 3 as a guardian of the tumor microenvironment","volume":"1863","author":"Ruvolo","year":"2016","journal-title":"Biochimica et Biophysica Acta-Molecular Cell Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109125_bb0880","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.bbamcr.2015.12.008","article-title":"Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells","volume":"1863","author":"Ruvolo","year":"2016","journal-title":"Biochimica et Biophysica Acta-Molecular Cell Research"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0885","series-title":"Conjugates","author":"Saarinen","year":"2020"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109125_bb0890","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1021\/acsmedchemlett.0c00671","article-title":"Novel galectin-3 inhibitors for treating fibrosis","volume":"12","author":"Sabnis","year":"2021","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb0895","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.autrev.2016.09.023","article-title":"Role of galectin-3 in autoimmune and non-autoimmune nephropathies","volume":"16","author":"Saccon","year":"2017","journal-title":"Autoimmunity Reviews"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109125_bb0900","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1016\/j.bmc.2010.05.040","article-title":"1H-1,2,3-triazol-1-yl thiodigalactoside derivatives as high affinity galectin-3 inhibitors","volume":"18","author":"Salameh","year":"2010","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0905","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1749-6632.2012.06475.x","article-title":"Glycans, galectins, and HIV-1 infection","volume":"1253","author":"Sato","year":"2012","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109125_bb0910","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.neulet.2011.09.015","article-title":"Increase of galectin-3 expression in microglia by hyperthermia in delayed neuronal death of hippocampal CA1 following transient forebrain ischemia","volume":"504","author":"Satoh","year":"2011","journal-title":"Neuroscience Letters"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109125_bb0915","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000495946","article-title":"Utility of cardiac biomarkers in the setting of kidney disease","volume":"141","author":"Savoj","year":"2019","journal-title":"Nephron"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109125_bb0920","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/ijms19020379","article-title":"Galectin-3: One molecule for an alphabet of diseases, from a to Z","volume":"19","author":"Sciacchitano","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109125_bb0925","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3390\/genes16101170","article-title":"Transcriptomic and clinical profiling reveals LGALS3 as a prognostic oncogene in pancreatic Cancer","volume":"16","author":"Scuderi","year":"2025","journal-title":"Genes"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109125_bb0930","doi-asserted-by":"crossref","first-page":"13047","DOI":"10.1074\/jbc.273.21.13047","article-title":"X-ray crystal structure of the human galectin-3 carbohydrate recognition domain at 2.1-\u00c5 resolution","volume":"273","author":"Seetharaman","year":"1998","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0935","doi-asserted-by":"crossref","DOI":"10.1016\/j.imu.2020.100411","article-title":"New clues arising from hunt of saccharides binding to galectin 3 via 3D QSAR and docking studies","volume":"21","author":"Sethi","year":"2020","journal-title":"Informatics in Medicine Unlocked"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109125_bb0940","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/13543776.2021.1903430","article-title":"An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016-present)","volume":"31","author":"Sethi","year":"2021","journal-title":"Expert Opinion on Therapeutic Patents"},{"issue":"7807","key":"10.1016\/j.pharmthera.2026.109125_bb0945","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109125_bb0950","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","article-title":"Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction","volume":"110","author":"Sharma","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0955","series-title":"Selenogalactoside Compounds for the Prevention and Treatment of Diseases Associated with Galectin and the Use Thereof","author":"Shechter","year":"2017"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109125_bb0960","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.acthis.2012.11.010","article-title":"The pleiotropic effects of galectin-3 in neuroinflammation: A review","volume":"115","author":"Shin","year":"2013","journal-title":"Acta Histochemica"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb0965","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1038\/s41467-019-11441-0","article-title":"Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington\u2019s disease","volume":"10","author":"Siew","year":"2019","journal-title":"Nature Communications"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109125_bb0970","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/aam.aam_56_18","article-title":"Inflammation and cancer","volume":"18","author":"Singh","year":"2019","journal-title":"Annals of African Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109125_bb0975","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2174\/157340606778250252","article-title":"A first QSAR model for galectin-3 glycomimetic inhibitors based on 3D docked structures","volume":"2","author":"Sirois","year":"2006","journal-title":"Journal of Medicinal Chemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109125_bb0980","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cmet.2016.10.014","article-title":"Gal3 links inflammation and insulin resistance","volume":"24","author":"Siwicki","year":"2016","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0985","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2020.105881","article-title":"The therapeutic potential of galectin-3 inhibition in fibrotic disease","volume":"130","author":"Slack","year":"2021","journal-title":"International Journal of Biochemistry & Cell Biology"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109125_bb0990","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.3390\/cells10113047","article-title":"Novel galectin-3 roles in neurogenesis, inflammation and neurological diseases","volume":"10","author":"Soares","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2026.109125_bb0995","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cca.2014.01.019","article-title":"Galectin-3 in cancer","volume":"431","author":"Song","year":"2014","journal-title":"Clinica Chimica Acta"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109125_bb1000","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1021\/ja043475p","article-title":"Structural and thermodynamic studies on cation-pi interactions in lectin-ligand complexes: High-affinity galectin-3 inhibitors through fine-tuning of an arginine-arene interaction","volume":"127","author":"Sorme","year":"2005","journal-title":"Journal of the American Chemical Society"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb1005","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/s41598-019-38497-8","article-title":"Extracellular and intracellular small-molecule galectin-3 inhibitors","volume":"9","author":"Stegmayr","year":"2019","journal-title":"Scientific Reports"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109125_bb1010","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1039\/D0OB00910E","article-title":"Efficient synthesis of a galectin inhibitor clinical candidate (TD139) using a Payne rearrangement\/azidation reaction cascade","volume":"18","author":"St-Gelais","year":"2020","journal-title":"Organic & Biomolecular Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109125_bb1015","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1006\/bbrc.1999.0291","article-title":"Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells","volume":"256","author":"Stitt","year":"1999","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109125_bb1020","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1182\/blood-2009-10-251660","article-title":"GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death","volume":"115","author":"Streetly","year":"2010","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109125_bb1025","first-page":"2927","article-title":"Biomarkers and heart disease","volume":"18","author":"Sun","year":"2014","journal-title":"European Review for Medical and Pharmacological Sciences"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109125_bb1030","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s00044-023-03087-x","article-title":"Discovery and exploration of monosaccharide linked dimers of galectin-3 inhibitors to target fibrosis","volume":"32","author":"Swidorski","year":"2023","journal-title":"Medicinal Chemistry Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109125_bb1035","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1007\/s00125-018-4552-z","article-title":"Galectin-3 is independently associated with progression of nephropathy in type 2 diabetes mellitus","volume":"61","author":"Tan","year":"2018","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb1040","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13578-021-00592-7","article-title":"Galectin-3: A key player in microglia-mediated neuroinflammation and Alzheimer\u2019s disease","volume":"11","author":"Tan","year":"2021","journal-title":"Cell & Bioscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb1045","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41418-019-0348-z","article-title":"Galectin-3 promotes a\u03b2 oligomerization and a\u03b2 toxicity in a mouse model of Alzheimer\u2019s disease","volume":"27","author":"Tao","year":"2020","journal-title":"Cell Death and Differentiation"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109125_bb1050","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1039\/b909091f","article-title":"Fragment-based development of triazole-substituted O-galactosyl aldoximes with fragment-induced affinity and selectivity for galectin-3","volume":"7","author":"Tejler","year":"2009","journal-title":"Organic & Biomolecular Chemistry"},{"issue":"12\u221213","key":"10.1016\/j.pharmthera.2026.109125_bb1055","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.carres.2007.03.012","article-title":"Synthesis of galactose-mimicking 1H-(1,2,3-triazol-1-yl)-mannosides as selective galectin-3 and 9N inhibitors","volume":"342","author":"Tejler","year":"2007","journal-title":"Carbohydrate Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109125_bb1060","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001535","article-title":"Combining inhibition of galectin-3 with and before a therapeutic vaccination is critical for the prostate-tumor-free outcome","volume":"8","author":"Tiraboschi","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109125_bb1065","doi-asserted-by":"crossref","first-page":"2232.e2231","DOI":"10.1016\/j.neurobiolaging.2012.05.001","article-title":"Genetic variation in galectin-3 gene associates with cognitive function at old age","volume":"33","author":"Trompet","year":"2012","journal-title":"Neurobiology of Aging"},{"issue":"43","key":"10.1016\/j.pharmthera.2026.109125_bb1070","doi-asserted-by":"crossref","first-page":"9620","DOI":"10.1002\/chem.202002084","article-title":"Regioselective 3-O-substitution of unprotected thiodigalactosides: Direct route to galectin inhibitors","volume":"26","author":"Va\u0161\u00ed\u010dek","year":"2020","journal-title":"Chemistry--A European Journal"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109125_bb1075","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HYPERTENSIONAHA.115.06161","article-title":"Inhibition of galectin-3 pathway prevents isoproterenol-induced left ventricular dysfunction and fibrosis in mice","volume":"67","author":"Vergaro","year":"2016","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109125_bb1080","doi-asserted-by":"crossref","first-page":"e1100","DOI":"10.1038\/cddis.2014.68","article-title":"Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors","volume":"5","author":"Veschi","year":"2014","journal-title":"Cell Death & Disease"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109125_bb1085","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/BF03401604","article-title":"Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): A new member of the AGE-receptor complex","volume":"1","author":"Vlassara","year":"1995","journal-title":"Molecular Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109125_bb1090","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1021\/acs.jmedchem.1c01625","article-title":"Glycopolymers decorated with 3-O-substituted thiodigalactosides as potent multivalent inhibitors of galectin-3","volume":"65","author":"Vrbata","year":"2022","journal-title":"Journal of Medicinal Chemistry"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109125_bb1095","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1158\/0008-5472.CAN-18-2244","article-title":"An orally active Galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade","volume":"79","author":"Vuong","year":"2019","journal-title":"Cancer Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109125_bb1100","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2019.152612","article-title":"Galectin-3 may serve as a marker for poor prognosis in colorectal cancer: A meta-analysis","volume":"215","author":"Wang","year":"2019","journal-title":"Pathology Research and Practice"},{"key":"10.1016\/j.pharmthera.2026.109125_bb1105","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.biopha.2016.01.014","article-title":"Molecular regulation of galectin-3 expression and therapeutic implication in cancer progression","volume":"78","author":"Wang","year":"2016","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2026.109125_bb1110","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.carbpol.2014.11.073","article-title":"An arabinogalactan from flowers of Panax notoginseng inhibits angiogenesis by BMP2\/Smad\/Id1 signaling","volume":"121","author":"Wang","year":"2015","journal-title":"Carbohydrate Polymers"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109125_bb1115","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2353\/ajpath.2009.080816","article-title":"Regulation of prostate Cancer progression by Galectin-3","volume":"174","author":"Wang","year":"2009","journal-title":"The American Journal of Pathology"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109125_bb1120","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1681\/ASN.V8111647","article-title":"Epithelial galectin-3 during human nephrogenesis and childhood cystic diseases","volume":"8","author":"Winyard","year":"1997","journal-title":"Journal of the American Society of Nephrology"},{"issue":"28","key":"10.1016\/j.pharmthera.2026.109125_bb1125","doi-asserted-by":"crossref","first-page":"18419","DOI":"10.1016\/S0021-9258(18)55075-4","article-title":"Carbohydrate-binding protein 35 (mac-2), a laminin-binding lectin, forms functional dimers using cysteine 186","volume":"266","author":"Woo","year":"1991","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb1130","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/molecules22010135","article-title":"Role of electron-driven proton-transfer processes in the ultrafast deactivation of photoexcited anionic 8-oxoGuanine-adenine and 8-oxoGuanine-cytosine base pairs","volume":"22","author":"Wu","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2026.109125_bb1135","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.biopha.2014.11.024","article-title":"Role of the interaction between galectin-3 and cell adhesion molecules in cancer metastasis","volume":"69","author":"Xin","year":"2015","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109125_bb1140","doi-asserted-by":"crossref","first-page":"6634","DOI":"10.1021\/acs.jmedchem.0c02001","article-title":"Synthesis, structure-activity relationships, and in vivo evaluation of novel Tetrahydropyran-based Thiodisaccharide mimics as Galectin-3 inhibitors","volume":"64","author":"Xu","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109125_bb1145","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1073\/pnas.93.13.6737","article-title":"Expression of galectin-3 modulates T-cell growth and apoptosis","volume":"93","author":"Yang","year":"1996","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109125_bb1150","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40618-014-0222-2","article-title":"Increased levels of galectin-3 were associated with prediabetes and diabetes: New risk factor?","volume":"38","author":"Yilmaz","year":"2015","journal-title":"Journal of Endocrinological Investigation"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb1155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168","article-title":"Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis","volume":"6","author":"Yu","year":"2013","journal-title":"Circulation. Heart Failure"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109125_bb1160","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10719-007-9034-3","article-title":"The oncofetal Thomsen\u2013Friedenreich carbohydrate antigen in cancer progression","volume":"24","author":"Yu","year":"2007","journal-title":"Glycoconjugate Journal"},{"key":"10.1016\/j.pharmthera.2026.109125_bb1165","series-title":"1,1\u2032-sulfanediyl-di-\u03b2-D-galactopyranosides as Inhibitors of Galectins","author":"Zetterberg","year":"2017"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109125_bb1170","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00744","article-title":"Pleiotropic regulatory mechanisms and targeted therapeutic prospects of Galectin-3 in aging-related diseases","volume":"22","author":"Yuan","year":"2025","journal-title":"Neurotherapeutics"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109125_bb1175","doi-asserted-by":"crossref","first-page":"12626","DOI":"10.1021\/acs.jmedchem.2c00660","article-title":"Discovery and optimization of the first highly effective and orally available galectin-3 inhibitors for treatment of fibrotic disease","volume":"65","author":"Zetterberg","year":"2022","journal-title":"Journal of Medicinal Chemistry"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109125_bb1180","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/cmdc.201700744","article-title":"Monosaccharide derivatives with low-Nanomolar lectin affinity and high selectivity based on combined fluorine-amide, phenyl-arginine, sulfur-pi, and halogen bond interactions","volume":"13","author":"Zetterberg","year":"2018","journal-title":"ChemMedChem"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109125_bb1185","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1021\/acsmedchemlett.3c00261","article-title":"Discovery of N-arylsulfonyl-indole-2-carboxamide derivatives as galectin-3 and galectin-8 C-terminal domain inhibitors","volume":"14","author":"Zhang","year":"2023","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109125_bb1190","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-025-00759-1","article-title":"Multifaceted roles of galectins: From carbohydrate binding to targeted cancer therapy","volume":"13","author":"Zhang","year":"2025","journal-title":"Biomarker Research"},{"key":"10.1016\/j.pharmthera.2026.109125_bb1195","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijcard.2018.04.025","article-title":"Galectin-3 is associated with left ventricular reverse remodeling and outcome after percutaneous mitral valve repair","volume":"263","author":"Zuern","year":"2018","journal-title":"International Journal of Cardiology"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582600152X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582600152X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:04:18Z","timestamp":1794413058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016372582600152X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":239,"alternative-id":["S016372582600152X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109125","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Galectin-3 and its inhibitors: Overview and perspectives","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109125"}}